Funding profile · Neurology care delivery

Synapticure

One Form D exists for this company. It reports $40,145,500 sold to 51 investors, filed two months before the $25 million Series A was announced. Federal grants add $5.18 million that cost no equity.

$40.1MSold on the company’s only Form D, filed Sep 24, 2024
51Investors on that filing, about $787,167 each
$5.18MNIH NINDS awards FY2022 to FY2026, non-dilutive
$1.0MRaised by a single-investor SPV in January 2020

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Jan 2020 Synapticure SPV I, LLC, pooled vehicle $1,000,000 1 investor; manager Synapticure Ventures, LLC; administrator Assure Fund Management II Form D
2020 Y Combinator, Summer 2020 Not disclosed Y Combinator YC data
Closed fall 2021, announced Feb 1, 2022 Seed $6,000,000 Led by GV; LifeForce Capital, Martin Ventures, Byers Capital, Y Combinator; angels including Ron Conway, Jeff Huber, Adam Koppel, Ben and Divya Silbermann Release
Sep 2024 Equity offering reported on Form D $40,145,500 offered and sold 51, not named Form D
Nov 19, 2024 Series A announced $25,000,000 Led by B Capital; CommonSpirit Health, CVS Health Ventures, RA Capital Management, Nexus NeuroTech Ventures; existing GV, Optum Ventures, Rock Health Capital Release
FY2022 to FY2026 Federal grants $5,175,078 NIH NINDS small business awards NIH

What the filings show

Synapticure, Inc. · Form D · filed Sep 24, 2024

First sale
Sep 9, 2024
Offered
$40,145,500 equity
Sold
$40,145,500 · $0 remaining
Investors
51 · average about $787,167
Exemption
Rule 506(b)
Issuer
Delaware corporation, incorporated 2019, Chicago IL · revenue range: Decline to Disclose
Related persons
Sandra Abrevaya (executive officer, director); Brian Wallach (director); Jason Langheier (director); Adam Seabrook (director); Peter Wallach, Joe Leinbach and Eric Anderson (executive officers)
Filing
SEC EDGAR, CIK 0002038193

Synapticure SPV I, LLC · Form D · filed Feb 6, 2020

First sale
Jan 31, 2020
Type
Pooled investment fund, Delaware LLC formed 2019
Sold
$1,000,000 of $1,000,000
Investors
1
Exemptions
Rule 506(b); Investment Company Act 3(c)(1)
Costs
$9,500, described in the filing as a one-time cost for fund organizational and operating expenses
Related persons
Synapticure Ventures, LLC (manager); Assure Fund Management II LLC (administrative manager); Richard Thoms (officer of the administrative manager)
Filing
SEC EDGAR, CIK 0001802424

Reading the filings

  1. The filing is bigger than the round.The Form D reports $40,145,500 sold. The press release six weeks later announced $25 million. The $6 million seed plus the $25 million Series A comes to $31 million, leaving $9.1 million unexplained by the two announced rounds. MedCity News put total capital raised at $40 million, which matches the filing rather than the headline. A Form D that shows the same figure offered and sold with nothing remaining is what you get when a filing sweeps in earlier tranches or converting notes alongside the new money.
  2. The checks are institutional size.$40,145,500 across 51 investors is about $787,167 each. That is a fund-sized average, consistent with the eight named venture and strategic investors plus a tail of smaller participants, not an angel crowd.
  3. The money was in before it was news.First sale Sep 9, 2024. Form D filed Sep 24. Announcement Nov 19. The round was closed and reported to the SEC 71 days before the press cycle.
  4. The earliest money on record predates the company’s own launch story.On Jan 31, 2020, a Delaware pooled fund called Synapticure SPV I, LLC took $1,000,000 from a single investor. It lists the same telephone number as the company’s 2024 Form D. The company dates its launch to February 2022.
  5. The board on paper is founders plus the lead.Directors named in 2024: Sandra Abrevaya, Brian Wallach, Jason Langheier and Adam Seabrook, the B Capital partner quoted as lead investor in the November release. No seat is listed for GV, which led the seed.
  6. An eighth of the capital came from NIH.$5,175,078 of grants against $40,145,500 of equity is about 11.4% of the $45.3 million total, and it funds a stem cell laboratory rather than the clinic.

Commercial signals

Signal Detail Source type
Payment model CMS GUIDE dementia model, live since Jul 1, 2024. Tiered monthly per patient care management fee plus up to $2,500 a year per patient for respite. New participant enrollment closed for the model’s eight year run. Public record
Referral channels ALS Association (Apr 2024), Pearl Health primary care referrals under GUIDE (Aug 2024), Biogen supporting ataxia education (Jul 2026). Partner-stated
Strategic holders CommonSpirit Health, CVS Health Ventures and Optum Ventures sit on the cap table, which puts a health system and two payer-affiliated funds behind a provider that bills payers. Release
Revenue “Decline to Disclose” on the 2024 Form D. No revenue figure has been published. Public record
Reported outcomes 25% fewer all-cause admissions and 19.6% fewer emergency department visits from baseline. Not located in any CMS document. Company-stated
Research line Five NINDS awards totaling $5,175,078; the current one runs to Apr 30, 2027. Public record

What to watch

  • A Form D for any raise after September 2024. Two years have passed with no new filing.
  • An amended Form D, which would settle whether the $40.1 million included converting earlier paper.
  • Whether CMS publishes participant-level GUIDE results.
  • Whether the strategic investors turn into named payer or health system contracts.
  • What happens to the organoid laboratory when the NINDS award ends in 2027.

The Synapticure story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Memora Health: Shared investor: B Capital. A text messaging platform that automated patient follow up for Mayo Clinic, Penn Medicine and more than fifty other provider organizations
  • Notable Labs: Shared investor: B Capital. A blood cancer company that screened drugs against a patient’s own cells to predict who would respond, in-licensed a shelved Boehringer Ingelheim compound, reached
  • Loop Health: Shared investor: Optum Ventures. A Pune company that sells group health insurance as a licensed broker and employs its own doctors to deliver the everyday care those policies do not cover
  • Medmonk: Shared investor: Rock Health. It began as a pharmacist’s spreadsheet for finding money for patients who could not pay for their drugs

Sources

  1. Public recordForm D, Synapticure, Inc.SEC · Sep 24, 2024
  2. Public recordForm D, Synapticure SPV I, LLCSEC · Feb 6, 2020
  3. Public recordNIH RePORTER, awards R44NS124457, R43NS134458, R44NS143521NINDS · FY2022 to FY2026
  4. Public recordGUIDE Model overview and payment termsCMS · accessed Sep 22, 2026
  5. IndependentSynapticure Secures $25M To Scale Virtual CareMedCity News · Nov 24, 2024
  6. IndependentSynapticure scores $25M to scale its platformMobiHealthNews · Nov 20, 2024
  7. IndependentSynapticure Raises $6M in Seed FundingFinSMEs · Feb 2, 2022
  8. CompanySynapticure Raises $25 Million Series APR Newswire · Nov 19, 2024
  9. CompanySynapticure Launches With $6M in Seed Funding Led by GVSynapticure · Feb 1, 2022
  10. CompanyCMS GUIDE and partners pagesSynapticure · Sep 22, 2026

Compiled from SEC, NIH and CMS public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Synapticure. This page is not an offer to sell or a recommendation to buy any security.